India Glycols grows revenue 30%, but input costs is concern
India Glycols Limited (NSE: INDIAGLYCO) reported revenue from operations of ₹358 crore in Q2 FY27, registering 30% year-on-year growth. For H1 FY27, revenue increased 26% to ₹713 crore. This is an important quarter for the company as it marks its first reported results as a focused chemicals business following the demerger of its spirits and biopharma businesses. Operating performance showed encouraging growth. EBITDA, including the share of joint venture earnings, increased 26% to ₹52 crore during the quarter. H1 EBITDA rose 25% to ₹113 crore. The performance chemicals segment was particularly strong. Its Q2 revenue increased 36% to ₹167 crore, while EBITDA grew 49% to ₹24 crore. The segment's EBITDA margin improved to 14.2% from 13% a year ago. Bio-based specialty materials also delivered healthy growth, with H1 revenue increasing 43% to ₹382 crore. However, EBITDA growth in this segment was slower at 15%, indicating pressure on profitability. The biggest challenge remains rising input and operating costs. Higher crude prices, expensive chemical raw materials, packaging costs and freight expenses have affected margins. The company has also acknowledged that passing on these cost increases to customers takes time. Management is targeting more than ₹200 crore in EBITDA for FY27, including joint venture contributions. The performance chemicals business is expected to play an important role in achieving this target. My view: India Glycols has an interesting position in bio-based and specialty chemicals, and the growth in performance chemicals is encouraging. However, revenue growth needs to translate into better margins and cash generation. Investors should track raw material costs, segment profitability and the company's ability to achieve its FY27 EBITDA target. The demerger provides a clearer view of the chemicals business, but consistent execution will determine its earnings potential. INDIAGLYCO



















